NCT06769906Completed
Effectiveness of Individualized Automatic Coaching Message for Glycemic Management and Depressive Symptom
Effectiveness of Individualized Automatic Target Coaching Message Based on the Metrics of Continuous Glucose Monitoring and Depressive Symptom in Patients With Insulin-treated Type 2 Diabetes: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 2 Jan 2026
Brief summary (registry, in English)
This is a 12-week, single-center, randomized, prospective, confirmatory study of effectiveness of the individualized automatic coaching messages for glycemic management based on continuous glucose monitoring and depressive symptom in insulin-treated patients with type 2 diabetes.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 46 (actual)
- First submitted
- 6 Jan 2025
- Start date
- 9 Jan 2025
- Primary completion date
- 2 Jul 2025
- Lead sponsor
- Samsung Medical Center
- Diseases
- Type 2 diabetes
- NCT number
- NCT06769906
What you commit to
- Study type: Interventional
- Participants enrolled: 46
- From 9 Jan 2025 to the primary completion date, 2 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Steroid and immunosuppressant users. But it can be included if patients continuously maintain same drug dose at least three months.
- Patients who are currently taking weight control medications.
Other
- Breastfeeding or pregnant patients
- Patients who do not voluntarily consent to the study
- Anyone deemed unsuitable by the investigator to participate in the study
Who the study is looking for
- Patients for whom the use of a continuous glucose monitor has been determined based on the medical judgment of the attending physician.
- Insulin-treated type 2 diabetes patients, age 18-80 years old.
- Patients who have not changed their diabetes medication in the past 2 months.
- Patients with a glycated hemoglobin level between 6.5% and 12.0% within the last 3 months.
- Patients currently receiving insulin injection therapy, including basal insulin.
- Patients who have access to KakaoTalk via smartphone and are able to communicate with it.
- Voluntarily agreed to participate in this clinical study.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Samsung Medical Center Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.